Difference between revisions of "Clear cell renal cell carcinoma"
| [unchecked revision] | [unchecked revision] |
| Line 26: | Line 26: | ||
== Genomic Gain/Loss/LOH == | == Genomic Gain/Loss/LOH == | ||
| − | + | chr1 Loss: 1p | |
| + | |||
| + | chr2 | ||
| + | |||
| + | chr3 Loss: 3p (3p21, 3p25 and/or 3p13-p14) | ||
| + | |||
| + | chr4 Loss: 4q | ||
| + | |||
| + | chr5 Gain: 5q | ||
| + | |||
| + | chr6 | ||
| + | |||
| + | chr7 | ||
| + | |||
| + | chr8 Loss: 8p | ||
| + | |||
| + | chr9 Loss: 9p, 9q | ||
| + | |||
| + | chr10 | ||
| + | |||
| + | chr11 | ||
| + | |||
| + | chr12 | ||
| + | |||
| + | chr13 | ||
| + | |||
| + | chr14 Loss: 14q | ||
| + | |||
| + | chr15 | ||
| + | |||
| + | chr16 | ||
| + | |||
| + | chr17 | ||
| + | |||
| + | chr18 | ||
| + | |||
| + | chr19 | ||
| + | |||
| + | chr20 | ||
| + | |||
| + | chr21 | ||
| + | |||
| + | chr22 | ||
| + | |||
| + | X | ||
| + | |||
| + | Y | ||
== Rearrangements == | == Rearrangements == | ||
Revision as of 20:43, 12 February 2016
Contributors
Daynna Wolff PhD FACMG
Tumor Type
Renal Cell Carcinoma
Tumor Classification
Clear Cell RCC
This tumor type accounts for 70-75% of all renal cell carcinoma cases (citation needed).
Description
Malignant epithelial cells with clear cytoplasm and a compact-alveolar (nested) or acinar growth pattern interspersed with intricate, arborizing vasculature. A variable proportion of cells with granular eosinophilic cytoplasm may be present. Infrequently, clear cell renal cell carcinoma has a distinct tubular pattern and rarely a pseudopapillary architecture is focally present."
IHC Markers
Positive: vimentin, CD10, RCC, PAX2, PAX8, CA-IX, EMA
Negative: CK7, CD117, AMACR, E-cadherin
Genomic Gain/Loss/LOH
chr1 Loss: 1p
chr2
chr3 Loss: 3p (3p21, 3p25 and/or 3p13-p14)
chr4 Loss: 4q
chr5 Gain: 5q
chr6
chr7
chr8 Loss: 8p
chr9 Loss: 9p, 9q
chr10
chr11
chr12
chr13
chr14 Loss: 14q
chr15
chr16
chr17
chr18
chr19
chr20
chr21
chr22
X
Y
Rearrangements
Write your comments here
Mutations (SNV/INDEL)
Write your comments here
From Cosmic Mutated in >20%
Mutated in 10-20%
Mutated in 5-10%
Mutated in 2-5%
mtDNA
Epigenomics (methylation)
Write your comments here
Main Pathways Involved
Write your comments here
Clinical Significance
Write your comments here
Diagnosis
Write your comments here
Prognosis
Write your comments here
Therapeutics
Write your comments here
Familial Forms
Write your comments here